Vitruvian BioMedical, Inc. logo

Vitruvian BioMedical, Inc.

VITRUVIAN BioMedical, is a biotechnology company engaged in the development and commercialization of diagnostics and therapeutics in the field of neurology oncology and metabolic diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.vitruvianbiomedical.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
16633 Dallas Pkwy #600, TX 75001
Addison
United States
Email
Contact Number

VITRUVIAN BioMedical, is a biotechnology company engaged in the development and commercialization of diagnostics and therapeutics in the field of neurology oncology and metabolic diseases.

Vitruvian BioMedicals in 2017 obtained exclusive License for a Therapeutic Vaccine YM7555 for Alzheimers Disease (AD) from Dr. Yoh Matsumoto from the Immunotherapy Development Inc. in Saitama, Japan and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

YM7555 is a DNA Vaccine that targets both ABeta and Tau that accumulates and supports development of AD. The vaccine stimulates an immune response resulting in antibodies that bind to and reduce ABeta and Tau. It also has Th2 immune response and does not elicit an inflammatory response in the brain. In addition, Vitruvian has also licensed from Dr. Matsumoto YM3711 that target only ABeta along with specifics for only TAU.